Volume 14 Supplement 1
6th International Conference on cGMP: Generators, Effectors and Therapeutic Implications
Meeting abstracts
Edited by John C Burnett Jr, Franz Hofmann, Kazuwa Nakao, Harald HHW Schmidt and Johannes-Peter Stasch
Publication of this supplement has been fully funded by Bayer Pharma AG. Johannes-Peter Stasch is an employee of Bayer Pharma AG, Wuppertal, Germany. He holds many patents on sGC stimulators and sGC activators. John C Burnett Jr is the chairman of the advisory board for Nile Therapeutics and is a Co-Founder and the Chief Scientific Officer for Zumbro Discovery. Mayo Clinic has licensed CD-NP to Nile Therapeutics and MANP to Zumbro Discovery. The other Supplement Editors declare that they have no competing interests.
6th International Conference on cGMP: Generators, Effectors and Therapeutic Implications. Go to conference site.
Erfurt, Germany28-30 June 2013
Page 2 of 3
-
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P13
-
Receptor guanylyl cyclase-G is a novel thermosensor in Grueneberg ganglion neurons involved in coolness-induced ultrasonic distress calls in mice
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P14 -
Synthesis and evaluation of bifunctional sGC regulators
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P15 -
A tissue based chemical proteomics screen to identify novel G-kinase associated proteins (GKAPs)
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P16 -
Defining the molecular targets of cerebellar PKG by quantitative (phospho)proteomics in a knock-out mouse model
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P17 -
The soluble guanylyl cyclase activator BAY 60-2770 ameliorates detrusor dysfunction in obese mice
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P18 -
A novel role of the natriuretic peptide/cGMP/cGKI pathway in melanoma cells
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P19 -
The soluble guanylyl cyclase stimulator BAY 41-2272 increases differentiation and function of brown adipocytes
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P20 -
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P21 -
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P22 -
Effects of age and gender on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P23 -
Guanylyl cyclase-B plays an important role in adipogenesis and “browning” of white fat
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P24 -
Soluble guanylyl cyclase as a therapeutic target in chronic obstructive pulmonary disease (COPD)
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P25 -
PDE3 is the major cGMP-PDE in adult mouse ventricular cardiomyocytes
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P26 -
Cardiovascular response to NO donors in mice deficient in NO-GC
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P27 -
The role of VASP in cGMP-mediated vascular smooth muscle relaxation
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P28 -
Urinary cGMP concentrations after exposure to radio-contrast media in patient at risk for contrast media induced nephropathy (CIN) predicts 90-day morbidity and mortality
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P29 -
Chronic activation of heme free soluble guanylate cyclase leads to cardio-renal protection in experimental hypertension
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P30 -
Cyclic GMP-mediated intercellular communication in mammalian ovarian follicles
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P31 -
Phosphodiesterase 5 is main regulator of brown adipocyte differentiation
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P32 -
Crystal structures of the carboxyl cGMP binding domain of plasmodium falciparumcGMP-dependent protein kinase reveals a novel salt bridge crucial for activation
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P33 -
Interstitial cells of Cajal plasticity rather than regeneration restores slow-wave activity and enteric neurotransmission upon acute damage
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P34 -
A bone overgrowth disorder due to a gain-of-function mutation in the kinase homology domain of guanylyl cyclase B, the receptor for CNP
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P35 -
Increases survival by apo-sGC activation via post-stroke blood brain barrier stabilisation and anti-inflammation
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P36 -
Localization and function of NO-GC in the murine gastrointestinal and lower urinary tract
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P37 -
A biodegradable in-situ polymer precipitation delivery system for sustained delivery of a novel chimeric natriuretic peptide CD-NP in an experimental model of myocardial infarction
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P38 -
Metabolic fate of orally administered cGMP in rats
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P39 -
Evidence for functional coupling of cGMP/cGKI signalling and TRPC channels in endothelium but not in vascular smooth muscle
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P40 -
Transforming PKA into PKG – a structure-function approach to understand cyclic nucleotide selectivity
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P41 -
Alternative splicing of α1 and β1 sGC genes is altered in aortic disease
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P42 -
M-atrial natriuretic peptide and nitroglycerin in experimental acute hypertensive heart failure: differential actions of two cGMP activating therapeutics
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P43 -
Video microscopy as a tool to visualize cGMP effects on contractility and sperm transport in seminiferous tubules and the epididymal duct
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P44 -
Endothelial dysfunction in adipose triglyceride lipase deficiency: role of perivascular adipose tissue
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P45 -
The good and the ugly: ANP antagonizes the deleterious effects of aldosterone in hypertensive cardiac remodeling
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P46 -
The effects of super-flux (high performance) dialyzer on the plasma glycosylated pro-B-type natriuretic peptide (proBNP) and glycosylated N-terminal proBNP in end-stage renal disease patients on dialysis
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P47 -
Impact of local CNP/GC-B system in growth plates on endochondral bone growth
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P48 -
Potent inhibition of nitroglycerin bioactivation by diphenyleneiodonium (DIP)
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P49 -
O-glycosylated pro-B-type natriuretic peptide is cleaved intracellularly by furin in ventricular and atrial myocytes: importance of the distance between the O-glycosylation and cleavage sites
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P50 -
ANP/GC-A signaling attenuates tissue injury by cisplatin
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P51 -
ANP/GC-A signaling attenuates pulmonary metastasis of B16 melanoma enhanced by lipopolysaccharide or angiotensin-II
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P52 -
Protective role of endogenous cardiac natriuretic peptide/GC-A system on the maternal heart during the postpartum period
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P53 -
Determination of cGMP levels in rodent tissues following oral dosing of a soluble guanylate cyclase stimulator
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P54 -
Platelet inhibitory effects of the NO independent sGC stimulator riociguat (Bay 63-2561)
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P55 -
The nitroxyl donor isopropylamine-NONOate elicits soluble guanylyl cyclase-dependent antihypertrophic actions: comparison of the potential therapeutic advantages of HNO over NO•
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P56 -
Soluble guanylyl cyclase mediates concomitant coronary vasodilator and positive inotropic actions of the HNO donor Angeli's salt in the intact rat heart
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P57 -
Protein kinase G oxidation contribute to hypotension and organ injury during sepsis
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P58 -
In striatum phosphodiesterase 10A is part of a synaptic signalling complex
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P59 -
Influence of PKG on insulin signalling and GSK3 phosphorylation in SH-SY5Y cells
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P60 -
Suppression of kidney fibrosis by cGMP-dependent protein kinase I
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P61 -
Fishing for elusive cCMP-degrading phosphodiesterases
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P62
Annual Journal Metrics
-
Citation Impact 2023
Journal Impact Factor: 2.8
5-year Journal Impact Factor: 2.8
Source Normalized Impact per Paper (SNIP): 0.774
SCImago Journal Rank (SJR): 0.710
Speed 2023
Submission to first editorial decision (median days): 25
Submission to acceptance (median days): 178
Usage 2023
Downloads: 790,731
Altmetric mentions: 400
Peer-review Terminology
-
The following summary describes the peer review process for this journal:
Identity transparency: Single anonymized
Reviewer interacts with: Editor
Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication